$Allarity Therapeutics (ALLR.US)$ It can be launched now, right? 🚀

$Allarity Therapeutics (ALLR.US)$ Why is there a Bullish outlook on $ALLR?
1) A solid scientific foundation
The clinical data of Allarity ($ALLR) is convincing! They utilize a precision oncology strategy with the PARP inhibitor Stenoparib targeting the WNT pathway, demonstrating astonishing potential. Their Phase II clinical trial was prematurely terminated due to significant efficacy—one patient achieved complete remission, while several others experienced significantly extended survival times. It is important to note that Stenoparib is mainly used as a last resort after all treatment options have failed, and such results are truly remarkable!
2) Market concerns: The issues of share issuance & reverse stock splits have eased.
Investors previously had concerns about share issuance and reverse stock splits, but the situation has now improved:
✅ CEO Thomas Jensen has explicitly committed to avoiding 'toxic financing' and will focus on enhancing Shareholder value.
The company has officially canceled the S-1 registration statement, significantly reducing the potential risk of dilution.
Currently, there is only about 10 million USD remaining in ATM financing (by my calculations), but considering the company's recent announcement of a 5 million USD Share Buyback, it is highly unlikely to be utilized. (The SEC generally does not encourage companies to engage in ATM financing while simultaneously repurchasing stocks.)
Currently, there is only one category of Stocks, and there are no impacts from debt conversions or warrants.
Regarding legal/regulatory issues.
In the past, Allarity faced challenges due to the mistakes of the previous management.

$Allarity Therapeutics (ALLR.US)$
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology
Monday, 17th March at 8:00 am
    
•The Annual Meeting is the foremost educational and scientific
event for gynecologic oncologists
•Stenoparib has shown clinical benefit in heavily pre-treated patients, including those with platinum-resistant and refractory ov...

$Allarity Therapeutics (ALLR.US)$ Allarity Therapeutics Presents Phase 2 Clinical Data From Ongoing Trial In Advanced Ovarian Cancer Patients At The 2025 Annual Meeting For The Society Of Gynecologic Oncology
Benzinga· 1 min ago
The Annual Meeting is the foremost educational and scientific
event for gynecologic oncologists
Stenoparib has shown clinical benefit in heavily pre-treated patients, including those with platinum-resistant and refractory ovarian cancer
Findings may reflect stenoparib...

$Allarity Therapeutics (ALLR.US)$
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration
Thursday, 6th March at 8:00 am
•Trial to explore novel combination therapy for patients with recurrent Small Cell Lung Cancer who have failed frontline treatment
•Fully funded by the U.S. Veterans' Administration Special Emphasis Panel on Precision Oncology
•Trial builds ...

After Trump confirmed the creation of a U.S. strategic crypto reserve, Bitcoin $Bitcoin (BTC.CC)$ has risen sharply, momentarily surpassing $94,000. However, it did not last long before Bitcoin turned around and fell again. Is it a pullback or a reversal?
Source: moomoo. Data as of March 3, 2025.
Factors affecting crypto
Since the U.S. election, Bitcoin has increasingly become a market investment wave, recognized as an emerging digital asset. As the pr...

$Allarity Therapeutics (ALLR.US)$
nfa

$Allarity Therapeutics (ALLR.US)$
Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit
Wednesday, 26th February at 8:00 am
Boston (February 26, 2025)—Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Respon...